Similar articles

• Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply.

  Downing NS, Shah ND, Ross JS. Downing NS, et al. JAMA. 2017 Sep 19;318(11):1067-1068. doi: 10.1001/jama.2017.11517. JAMA. 2017. PMID: 28975302 No abstract available.
• US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.

  Eadie A, MacGregor A, Wallach J, Ross J, Herder M. Eadie A, et al. BMJ Evid Based Med. 2023 Jun;28(3):151-156. doi: 10.1136/bmjebm-2022-112005. Epub 2023 Mar 21. BMJ Evid Based Med. 2023. PMID: 36944478
• Postmarket surveillance. Final rule.

  Food and Drug Administration, HHS. Food and Drug Administration, HHS. Fed Regist. 2002 Jun 6;67(109):38878-92. Fed Regist. 2002. PMID: 12053947
• An overview of FDA medical device regulation as it relates to deep brain stimulation devices.

  Peña C, Bowsher K, Costello A, De Luca R, Doll S, Li K, Schroeder M, Stevens T. Peña C, et al. IEEE Trans Neural Syst Rehabil Eng. 2007 Sep;15(3):421-4. doi: 10.1109/TNSRE.2007.903973. IEEE Trans Neural Syst Rehabil Eng. 2007. PMID: 17894274 Review.
• Overview of contact lens postmarket surveillance in the United States: system and recent study results.

  Chalmers RL, Gleason W. Chalmers RL, et al. Eye Contact Lens. 2013 Jan;39(1):109-14. doi: 10.1097/ICL.0b013e31827c9939. Eye Contact Lens. 2013. PMID: 23266591 Review.